The Atmo® Gas Capsule a world-first ingestible gas-sensing capsule to provide unique insights into gut health and microbiome function.

The gas-sensing capsule assesses the functional health of a patient’s entire gastrointestinal system and aims to provide: better diagnosis, more targeted and personalized treatment, earlier relief of symptoms and improved healthcare outcomes.

The capsule can electronically report important data by continuously detecting gases and wirelessly transmitting the data to provide insights into the location of the capsule, microbiome function and gastrointestinal health.

The ingestible capsule offers a potential diagnostic tool for many disorders of the gut from motility disorders, IBS and IBD to liver disease.

The Atmo Gas Capsule is currently an investigational device exclusively for use in clinical investigations, and is not available for sale.

Gut disorders are common and debilitating

Gut disorders are one of the most common ailments in the world affecting tens of millions of people.
These disorders include motility abnormalities, SIBO, IBS and IBD. Gases are important biomarkers of disease, dysfunction and dysbiosis.


40% of global population suffer from a Functional Gastrointestinal Disorder (FGID).


30% of patients remain undiagnosed and suffer from the recurrence of disorders.


IBS affects 25 to 45 million people in the USA and 2 to 5 million in Australia.


GI disorders and disease treatment market (2013 USD).

How the Atmo Gas Capsule works

The vitamin-sized electronic “Lab-in-a-Pill” measures gaseous biomarkers at the source of production as it passes through the gastrointestinal system. This data is continuously transmitted to a pocket-sized receiver, and sent to the cloud for aggregation, analysis, and diagnosis.

The gas sensors are sealed within a special membrane that allows gas in but keeps out stomach acid and digestive juices.

The capsule aims to determine transit times derived from measures of temperature, relative humidity, hydrogen concentration, and carbon dioxide concentration, in conjunction with indicators of multi-gas, capsule tumble, and antenna reflectance.

Media coverage
“Gases produced in the gut are clinically valuable biomarkers for gastrointestinal health and dysfunction.”

Kalantar-Zadeh, K., Berean, K.J., Burgell, R.E. et al. Intestinal gases: influence on gut disorders and the role of dietary manipulations. Nat Rev Gastroenterol Hepatol 16, 733–747 (2019).

Medical Advisory Board

Prof. Eamonn Quigley

Houston Methodist Hospital, Weill Cornell Medical College

Professor Peter Gibson

Prof. Peter Gibson

Monash University, The Alfred

Prof William D. Chey

Prof William D. Chey

University of Michigan

Prof. Satish Rao

Prof. Satish Rao

Augusta University

Dr Braden Kuo

Assoc. Prof. Braden Kuo

Massachusetts General Hospital, Harvard Medical School

Prof. Anthony Lembo

Prof. Anthony Lembo

Cleveland Clinic

Prof. Lin Chang

Prof. Lin Chang

University of California

Malcolm Hebblewhite

Malcolm Hebblewhite

CEO and Co-Founder

Kate Hill

Kate Hill

Chair of the Board & Non-Executive Director

Chris Roberts

Dr. Chris Roberts AO

Non-Executive Director

Chris Bertrand

Chris Bertrand

Non-Executive Director

Dr Kyle Berean

Dr. Kyle Berean

VP Technology and Co-Founder

James John

Dr. James John

VP Operations and Co-Founder

Sue Dafnias

Sue Dafnias

Head of Commercial

Dr Carl Runde

Dr. Carl Runde

Chief Financial Officer

Adam Chrimes

Dr. Adam Chrimes

Principal Engineer and Co-Founder

Matt Reeves

Manufacturing Manager

Prof Kourosh Kalantar zadeh

Professor Kourosh Kalantar-zadeh

Lead Scientific Advisor